Global InformationKevin Slawin information
Kevin M. Slawin | |
|---|---|
| Born | 1961 Brooklyn, New York, United States |
| Education | BA Columbia University MD Columbia University College of Physicians & Surgeons |
| Occupation(s) | Prostate cancer physician and biotechnology entrepreneur |
| Known for | Co-discoverer of P2PSA, a key component of the Prostate Health Index test (phi test) and founder of Bellicum Pharmaceuticals, Inc. |
Kevin M. Slawin (born 1961) is an American physician and the founder of Bellicum Pharmaceuticals and the Vanguard Urologic Institute at Memorial Hermann Medical Group. He was also the Director of Urology at Memorial Hermann Hospital. Slawin specializes in the diagnosis and treatment of urologic cancers and robotic surgery. He is also possesses patents related to the advancement of prostate cancer diagnosis, staging and treatment[1] and to the cellular immunotherapy of cancer.
- ^ "New prostate cancer test gives more specific, reliable results". Chron.cosm. 25 June 2014. Retrieved 27 January 2015.